(20)Commission Implementing Regulation (EU) 2021/745note extended the approval period of flumioxazin to 30 June 2022 in order to allow the renewal process to be completed before the expiry of that approval period. However, given that a decision to renew the approval has been taken ahead of that extended expiry date, this Regulation should apply as soon as possible.
Source: EUR-Lex, © European Union, 1998-2026. Reuse authorised under Decision 2011/833/EU.